R
Robert W. Baker
Researcher at Eli Lilly and Company
Publications - 91
Citations - 6148
Robert W. Baker is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Olanzapine & Bipolar disorder. The author has an hindex of 35, co-authored 89 publications receiving 5938 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression
Mauricio Tohen,Mauricio Tohen,Eduard Vieta,Joseph R. Calabrese,Terence A. Ketter,Gary S. Sachs,Charles L. Bowden,Philip B. Mitchell,Franca Centorrino,R.C. Risser,Robert W. Baker,Angela R. Evans,Karin Beymer,Sanjay Dubé,Sanjay Dubé,Gary D. Tollefson,Alan Breier +16 more
TL;DR: Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms.
Journal ArticleDOI
A symptom rating scale for delirium.
TL;DR: Compared to demented, schizophrenic, and normal control groups, 20 delirious subjects scored significantly higher on the scale, which quantitates multiple parameters affected by delirium.
Journal ArticleDOI
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Mauricio Tohen,Mauricio Tohen,K. N. Roy Chengappa,Trisha Suppes,Carlos A. Zarate,Joseph R. Calabrese,Charles L. Bowden,Gary S. Sachs,David J. Kupfer,Robert W. Baker,Richard C. Risser,Elisabeth L. Keeter,Peter D. Feldman,Gary D. Tollefson,Alan Breier +14 more
TL;DR: Compared with the use of valproate or lithium alone, the addition of olanzapine provided superior efficacy in the treatment of manic and mixed bipolar episodes.
Journal ArticleDOI
Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.
Mauricio Tohen,Waldemar Greil,Joseph R. Calabrese,Gary S. Sachs,Lakshmi N. Yatham,Bruno Müller Oerlinghausen,Athanasios Koukopoulos,Giovanni B. Cassano,Heinz Grunze,Rasmus Wentzer Licht,Liliana Dell'Osso,Angela R. Evans,Richard C. Risser,Robert W. Baker,Heidi Crane,Martin Dossenbach,Charles L. Bowden +16 more
TL;DR: It is suggested that olanzapine was significantly more effective than lithium in preventing manic and mixed episode relapse/recurrence in patients acutely stabilized with olanZapine and lithium co-treatment.
Journal ArticleDOI
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.
Mauricio Tohen,Terence A. Ketter,Carlos A. Zarate,Trisha Suppes,Mark A. Frye,Lori L. Altshuler,John Zajecka,Leslie M. Schuh,Richard C. Risser,Eileen Brown,Robert W. Baker +10 more
TL;DR: Over 47 weeks, mean improvement in Young Mania Rating Scale score was significantly greater for the olanzapine group, and median time to symptomatic mania remi...